Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia.
A remarkably high rate of adverse events is associated with the use of trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus type 1 infection. We examined the efficacies of sulfonamides alone in the prevention of Pneumocystis carinii pneumonitis, with the assumption that at least some of the adverse events with the drug combination might be due to trimethoprim. With the immunosuppressed rat model, eight sulfonamides were studied at 100, 10, and 1.0 mg/kg/day (10 rats per dosage and drug). P. carinii infection was prevented in all animals (100%) receiving dosages of as little as 1.0 mg of sulfamethoxazole, sulfamethoxypyridazine, and sulfadimethoxine per kg per day, as little as 10 mg of sulfameter, sulfachlorpyridazine, and sulfaquinoxaline per kg per day; and 100 mg of sulfaguanidine and sulfanilamide per kg per day. These studies suggest that a sulfonamide, such as sulfamethoxazole, might provide effective prophylaxis for P. carinii pneumonitis without trimethoprim.
Hughes
W T
WT
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Killmar
J
J
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D008297:Male; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013412:Sulfadimethoxine / Q000627:therapeutic use; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013421:Sulfamethoxypyridazine / Q000627:therapeutic use
D000890:Anti-Infective Agents; D013412:Sulfadimethoxine; D013420:Sulfamethoxazole; D013421:Sulfamethoxypyridazine